ARES RNA Circuits for Spatial and Temporal mRNA Stability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA therapies lack precise spatial and temporal control over mRNA stability, leading to potential side effects and inefficiencies.
Innovation Solution
The integration of RNA-binding proteins (RBPs) with self-cleaving ribozymes into aptamer and ribozyme equilibrium shifting (ARES) RNA circuits, allowing for precise control of mRNA stability through stabilizing or destabilizing switches triggered by RBPs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If mRNA stability is regulated through cap structures and polyadenylation, then mRNA lifespan is prolonged, but precise spatial and temporal control over mRNA stability is lacking
Solution Approach 1:
The patent employs dynamic RNA switches that can transition between different functional states (ON/OFF) in response to cellular signals. These switches allow the mRNA stability to be dynamically adjusted at specific times and locations, providing both prolonged lifespan when needed and precise temporal control when activation or deactivation is required.
Solution Approach 2:
The patent introduces localized control mechanisms where RNA switches can be positioned at specific locations within the cell (e.g., near the ribosome or in specific subcellular compartments). This allows different regions of the cell to have different mRNA stability characteristics, enabling spatial control of gene expression while maintaining overall mRNA lifespan.
2Adaptability or versatility
If mRNA therapies are delivered systemically, then therapeutic coverage is improved, but side effects and off-target effects increase
Solution Approach 1:
The patent incorporates feedback mechanisms where RNA switches monitor cellular conditions (such as the presence of specific proteins or metabolites) and adjust mRNA stability accordingly. This feedback allows the system to activate therapy only in cells with specific characteristics, providing adaptability while minimizing side effects in cells where the therapy is not needed.
Solution Approach 2:
The patent utilizes changes in cellular parameters (such as protein expression levels, metabolite concentrations, or post-translational modifications) as triggers for RNA switch activation. By tying therapy activation to specific parameter changes, the system achieves versatile therapeutic coverage while ensuring that therapy is only delivered when and where it is biologically appropriate, thereby reducing side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides enhanced spatial and temporal control over mRNA therapeutics, reducing side effects and improving therapeutic efficacy.
Implementation Method 1
self-cleaving ribozymes (e.g., hammerhead ribozyme, HHR)
Implementation Method 2
protein-binding aptamer that specifically binds to a target protein
Data Source
AI summary
The technology described herein is directed to Aptamer and Ribozyme Equilibrium Shifting (ARES) regions, including ON-switches and OFF-switches, which can be harnessed to regulate the stability of RNA molecules. Also described herein are compositions comprising such RNA molecules and methods of using them to regulate translation of cargo polypeptides.